Results 61 to 70 of about 34,440,044 (184)

Retatrutide-Induced Intractable Diarrhea

Annals of Internal Medicine: Clinical Cases
Gastrointestinal symptoms accompanying the use of glucagon-like peptide-1 (GLP-1) receptor agonists and glucose-dependent insulinotropic polypeptide receptor-GLP-1 receptor co-agonists have been extensively catalogued.
Opeyemi Komolafe
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Hidradenitis Suppurativa

International audienceThis cohort study investigates the potential therapeutic benefits of glucagon-like peptide-1 receptor agonists in patients with hidradenitis ...
Maruani, A, Oules, Bénédicte, Pruvost-Balland, Christelle, Safa, Gilles, Fayad, Alice, Brun, Aurore, Nassif, Aude, Tardieu, Mathilde, Quéreux, Gaëlle, Buche, Sebastien, Guenego, Agathe, Delage, Maïa, P. Villani, Axel, Fite, Charlotte, Misery, Laurent, Le Naour, Sarah, Cassius, Charles, Dupuy, Alain, Gouvrion, Louise, Thibault, Ronan, Poizeau, Florence   +20 more
core   +1 more source

Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes

, 2017
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects.
Deborah Hinnen
core   +1 more source

Effect of glucagon-like peptide-1 receptor agonists on body weight and urinary albumin-to-creatinine ratio in patients with and without type 2 diabetes: A systematic review and meta-analysis

Journal of International Medical Research
Objective Glucagon-like peptide-1 receptor agonists are established for weight management and cardiovascular risk reduction, with emerging evidence for kidney protection.
Rong Huang, Bin Wang
doaj   +1 more source

Obesity and hypertension in type 2 diabetes: exploring central and peripheral effects of glucagon-like peptide-1 receptor signalling

Glucagon-like peptide 1 is a hormone involved in the regulation of glucose. Glucose-dependent activation of brain GLP-1R stimulates GLP-1 secretion from the L-cells of the intestine in response to ingested nutrients and it enters the blood stream to ...
Robinson, Louise E.
core  

Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists

Diabetes & Metabolism
Glucagon-like peptide-1 (GLP-1) is an incretin hormone, secreted from gut endocrine cells, which acts to potentiate nutrient-induced insulin secretion. Activation of its receptor, GLP-1R, decreases glucagon secretion and gastric emptying, thereby decreasing blood glucose and body weight. It is largely through these mechanisms that Glucagon-like peptide-
J Chen, ME Cooper, MT Coughlan
openaire   +2 more sources

Glucagon like peptide 1 receptor agonists: therapy for diabetes management

, 2017
Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.
Granados Vega, Elkyn Johan, Rojas, Natalia Andrea   +1 more
core   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists: Beta-Cell Protection or Exhaustion?

, 2016
Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells.
Verchere, C Bruce, van Raalte, Daniël H
core   +1 more source

Effect of Glucagon‐Like Peptide 1 Receptor Agonists on Patients With Rheumatoid Arthritis

ACR Open Rheumatology
Objective Glucagon‐like peptide 1 receptor agonists (GLP‐1RAs) are approved for weight loss, diabetes, and cardiovascular risk reduction. Despite widespread use, GLP‐1RAs have not been well studied in patients with rheumatoid arthritis (RA).
David A. Kellner, Elizabeth Dente, Vincent Tran, Travis Welsh, Victor Tran, Angshuman Saha, Joshua F. Baker, David A. Elashoff, Veena K. Ranganath   +8 more
doaj   +1 more source

Glucagon like peptide 1 receptor agonists: a therapy for diabetes management

, 2018
Introduction: Glucagon-like peptide 1 agonists inhibit glucose-dependent glucagon secretion, decrease gastric emptying and appetite through neural mechanisms, contribute to glucose regulation and show reduction in glycated hemoglobin A.
Elkyn Johan Granados-Vega, Natalia Andrea Rojas-Henao, Granados Vega, Elkyn Johan, Rojas Henao, Natalia Andrea   +3 more
core   +1 more source